For & Against
What's Next
Centene enters its most consequential earnings cycle in years. The Q1 2026 report on April 28 — three days away — will deliver the single most important data point in this name: the first-quarter Medicaid HBR. Everything else — valuation, operating leverage, management credibility — is secondary to whether the Q4 2025 improvement was structural or seasonal. Beyond earnings, three catalysts in the next six months will shape the stock's trajectory.
The market is focused almost entirely on April 28. The consensus estimate of $2.12 EPS implies the street is pricing in modest improvement from FY2025's run rate, but the real signal is not EPS — it is the Medicaid HBR. A print below 93% would confirm that 2026 rate catch-ups are exceeding medical cost trend for the first time since redeterminations began. A print above 93.5% would suggest the Q4 2025 improvement was seasonal, putting the full-year "above $3" guidance at risk. Beyond earnings, the OBBBA work requirements effective January 2027 represent the next structural overhang — an unquantified second wave of Medicaid member attrition that neither side has fully priced.
For / Against / My View
For
1. Historically cheap on normalized cash flow
At 0.11x price-to-sales and 3.3x EV/EBITDA on FY2024 clean earnings, CNC is the cheapest large-cap managed care stock in a generation. The company generated $5.1B in operating cash flow in FY2025 — a year with negative reported net income — against a $20.6B market cap, and ended the year in a net cash position ($17.9B cash vs $17.5B debt). The 5-year average FCF of $3.9B implies a 19% FCF yield that prices in permanent margin impairment the data does not support.
Evidence: 0.11x P/S is the lowest in CNC's publicly traded history and the lowest among large-cap MCO peers; 3.3x EV/EBITDA vs managed care industry median of 10-11x; net debt of -$0.3B at FY2025 year-end.
2. Medicaid HBR inflection is confirmed, not speculative
Medicaid HBR improved 190 bps from 94.9% in Q2 2025 to 93.0% in Q4 2025 — a trajectory that is accelerating, not decelerating. The composite rate adjustment matured to 5.5% in FY2025, and states now have two full years of post-redetermination acuity data in their actuarial bases for 2026 rate-setting. Management expects "mid-fours" net medical cost trend in 2026, meaning rate increases will exceed cost trend for the first time since redeterminations began.
Evidence: Medicaid HBR trajectory Q2 94.9% to Q3 93.4% to Q4 93.0%; FY2025 composite rate adjustment 5.5% vs initial 5% assumption; 2026 rate conversations described as "constructive."
3. Extreme operating leverage creates asymmetric upside
On $124B of Medicaid premium revenue, every 100 bps of HBR improvement releases approximately $1.2B in pre-tax earnings — roughly $2.00 per share after tax. Getting from the current 93.7% to the pre-redetermination baseline of 91-92% would add $2-3B in annual pre-tax income, translating to $4-5 per share of incremental EPS. The stock at $42 prices in zero of this recovery beyond the conservative $3.00 floor guidance.
Evidence: 100 bps HBR equals roughly $1.2B profit swing on $124B Medicaid premium base; FY2024 clean EPS was $7.17 with Medicaid HBR at 92.5%; FY2024 represents achievable margin levels, not an aberration.
Bull Price Target
FY2027E Adj. EPS
Forward P/E Applied
Bull timeline: 12-18 months. Primary catalyst is Q1 2026 earnings on April 28 — a Medicaid HBR print below 93% confirms the recovery trajectory and forces consensus estimates higher from the $3.01 floor.
Against
1. Scale never translated to margins — Molina proves it
Centene grew revenue 4x from $41B (2016) to $195B (2025) through serial acquisitions, yet operating margins compressed from 2.5-3.5% pre-WellCare to under 2% post-WellCare, with FY2025 adjusted operating income at negative $900M. Molina runs the same Medicaid business at one-quarter the scale and generates 4.2% operating margins versus Centene's 1.9%. The $6.7B goodwill impairment is management's own admission that 40% of acquisition-era value was illusory. Nine years of post-acquisition data show the margin gap with peers is structural, not cyclical.
Evidence: Operating margins 0.9%-3.1% since 2016 with no upward trend; MOH at 4.2% vs CNC at 1.9% on FY2024 clean numbers. Adjusted operating income approximately -$900M in FY2025 even excluding the impairment; goodwill dropped from $17.6B to $10.8B.
2. Marketplace repricing is an unproven experiment at dangerous scale
EAPTC expiration will shrink Marketplace membership from 5M to approximately 3.5M — a 30% contraction. Management responded with mid-30% average rate increases and a shift to a Bronze-heavy mix (above 30% of enrollment, up from 19-24% historically). This Bronze-centric model is untested at Centene's scale. Wakely actuarial data confirmed the morbidity was structural, not transient, requiring an additional $275M in provisions in H2 2025 alone. One adverse selection spiral in a lower-subsidy environment wipes out the 4% pretax margin target on a $45B revenue segment.
Evidence: Marketplace morbidity confirmed structural by Wakely; $75M additional provision added Q3 on top of $200M already reserved. Bronze-heavy mix unproven; pretax margin target of 4% never achieved in this configuration. Commercial HBR surged from 77% (FY2024) to 85% (FY2025) — an 800 bps deterioration in one year.
3. Guidance credibility is broken after the worst miss in MCO history
Management guided FY2025 at "more than $7.25" EPS and delivered $2.08 — a 71% shortfall. The Medicaid acuity mismatch was flagged as early as Q2 2024, a full year before guidance was set, yet management maintained it. The FY2026 "above $3" guide represents under half the FY2024 peak of $7.17, and management's own framing — conservative floor, not midpoint — signals they do not trust their own forecasting on this business. The pattern is clear: acknowledge problems, redirect to a recovery narrative, and hope the timeline compresses.
Evidence: Initial $7.25 guide delivered at $2.08. The 12-15% long-term EPS growth target, first stated in Q3 2024, was quietly abandoned. Insider ownership at 0.31% — management has negligible personal wealth at risk if forecasts miss again.
Bear Downside Target
FY2026E EPS (Bear)
Trough P/E Applied
Bear timeline: 12-18 months through Q3 2026 earnings. Primary trigger is Q1 or Q2 Medicaid HBR above 93%, confirming the rate catch-up narrative has stalled and the "above $3" guidance is unachievable.
The Tensions
1. Medicaid HBR at 93%: recovery confirmed or seasonal aberration?
Bull says the Q2-to-Q4 2025 trajectory (94.9% to 93.0%) is accelerating structural recovery as composite rate adjustments of 5.5% begin exceeding medical cost trend. Bear says the full-year 93.7% is still 170-270 bps above the 91-92% pre-redetermination baseline, and the Q4 improvement could reflect seasonal patterns rather than structural repricing. Both cite the same 190 bps Q2-Q4 improvement and the same 93.7% full-year figure — they disagree on whether the slope or the level tells the true story. This resolves on the Q1 2026 Medicaid HBR print on April 28 — three days from now.
2. $195B of revenue: operating leverage or structural margin drag?
Bull says every 100 bps of HBR improvement on $124B of Medicaid premiums releases approximately $1.2B in pre-tax earnings — the leverage is real and asymmetric at this scale. Bear says revenue grew 4x from $41B to $195B post-WellCare while operating margins compressed from 2.5-3.5% to under 2%, and Molina generates 4.2% operating margins at one-quarter the scale — proving the margin deficit is structural, not cyclical. Both cite the same revenue base and the same margin history; they disagree on whether scale is an asset or a liability. This resolves on whether FY2026 operating margins expand above 2% as rate catch-ups mature through H1 2026.
3. FY2024's $7.17 EPS: achievable baseline or unrepeatable peak?
Bull calls FY2024 performance "achievable margin levels, not an aberration" and builds a $68 target on recovering toward $5.00 EPS by FY2027. Bear calls the same $7.17 peak "inflated by favorable Marketplace risk adjustments and pre-redetermination Medicaid economics that are not repeatable" — a high-water mark the business will not revisit. Same number, opposite reads on whether it represents normalized earnings power or a one-time confluence. This resolves as Medicaid HBR and Marketplace margin data accumulate through H1 2026.
My View
I lean cautiously toward the bulls, but the margin of confidence is thin. The HBR trajectory from Q2 to Q4 2025 — 190 bps of improvement on a $124B premium base — is the most important data in this name, and it is moving the right direction; that is not rounding error. If Q1 prints below 93% on April 28, the operating leverage argument becomes compelling and the stock is genuinely cheap at 0.11x sales with a net cash balance sheet. But the credibility gap is severe: a management team that guided $7.25 and delivered $2.08 has not earned the benefit of the doubt, and the Marketplace repricing experiment is untested at this scale. I would wait for the April 28 print before committing — if Medicaid HBR comes in below 93%, the risk-reward tilts meaningfully bullish; if it prints above 93.5%, the recovery narrative stalls and the bear case gains weight.